Company
Headquarters: Guangzhou, China
Employees: 1,348
CN¥2.60 Billion
CNY as of Jan. 1, 2024
US$365.9 Million
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pediatric medicines in China. It offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine. The company markets its products through a network of agents and sales terminals. The company was formerly known as HaiNan Honz Pharmaceutical Co.,Ltd. and changed its name to Honz Pharmaceutical Co., Ltd. in November 2016. Honz Pharmaceutical Co., Ltd. is headquartered in Guangzhou, China.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Honz Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300086 wb_incandescent